VDRM (ViaDerma) EPS without NRI: $17.00 (TTM As of Jun. 2012)


What is ViaDerma EPS without NRI?

ViaDerma VDRM EPS without NRI is $17.00 as of Jun. 2012.

ViaDerma's earnings per share without non-recurring items for the three months ended in Jun. 2012 was $7.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2012 was $17.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for ViaDerma's EPS without NRI or its related term are showing as below:

VDRM's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.7
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

ViaDerma's EPS (Diluted) for the three months ended in Jun. 2012 was $7.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2012 was $17.00.

ViaDerma's EPS (Basic) for the three months ended in Jun. 2012 was $7.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2012 was $17.00.


ViaDerma  (OTCPK:VDRM) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


ViaDerma EPS without NRI Related Terms


ViaDerma EPS without NRI Historical Data

* Premium members only.

The historical data trend for ViaDerma's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViaDerma EPS without NRI Chart

ViaDerma Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11
EPS without NRI
-12.60 49.50 29.50 33.01 19.51

ViaDerma Quarterly Data
Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.50 3.00 4.00 3.00 7.00

VDRM vs AOLS, RDGL, PCYN: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ViaDerma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViaDerma PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ViaDerma's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where ViaDerma's PE Ratio without NRI falls into.



ViaDerma EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $17.00 mean?
ViaDerma (VDRM) has a EPS without NRI of $17.00 as of Jun. 2012. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on ViaDerma and its competitors.
Is ViaDerma's EPS without NRI too high?
ViaDerma's current EPS without NRI is $17.00. The Drug Manufacturers industry median EPS without NRI is 9.70. ViaDerma's value of $17.00 is 75.3% above this industry median.
How does ViaDerma's EPS without NRI compare to AOLS and RDGL?
ViaDerma's EPS without NRI of $17.00 can be compared against companies in the Drug Manufacturers industry. The industry median EPS without NRI is 9.70. ViaDerma's value of $17.00 is 75.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ViaDerma's current EPS without NRI of $17.00 is 75.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on ViaDerma and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViaDerma's current EPS without NRI is $17.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViaDerma stock overvalued right now?
ViaDerma (VDRM) has a current EPS without NRI of $17.00. The current EPS without NRI is $17.00 and 75.3% above the Drug Manufacturers industry median of 9.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For ViaDerma (VDRM), the current EPS without NRI is $17.00 as of Jun. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ViaDerma Business Description

Address 4640 Admiralty Way, Suite 500, Marina Del Rey, CA, USA, 90292
ViaDerma Inc is a specialty pharmaceutical company focused to bring new products to market through research and development. It is engaged in the business of manufacturing and sales of pharmaceuticals, and specifically topical antibiotics and pain management in the United States of America. Its sells under the brand name Vitastem. The Company also has products in development in the fields; anti-aging skin care, pain management, hair-loss, and toenail fungus.